Novo Nordisk A/S (NVO) Free Cash Flow (FCF): $4.85B
The free cash flow (FCF) for Novo Nordisk A/S (NVO) is $4.85B. It is below its 12-month average by 31.66% ($7.09B).
NVO Free Cash Flow (FCF) Chart
NVO Average Free Cash Flow (FCF) Chart
NVO Current vs Average Free Cash Flow (FCF) Chart
NVO Free Cash Flow (FCF) Metrics
FREE CASH FLOW (FCF)
$4.85B
FREE CASH FLOW (FCF) AVG TTM
$7.09B
FREE CASH FLOW (FCF) AVG 3Y
$8.44B
FREE CASH FLOW (FCF) AVG 5Y
$7.65B
FREE CASH FLOW (FCF) AVG 10Y
$6.52B
FREE CASH FLOW (FCF) AVG 15Y
$4.64B
FREE CASH FLOW (FCF) AVG 20Y
$3.76B
CURRENT VS TTM AVG
-31.66%
CURRENT VS 3Y AVG
-42.55%
CURRENT VS 5Y AVG
-36.66%
CURRENT VS 10Y AVG
-25.65%
CURRENT VS 15Y AVG
+4.50%
CURRENT VS 20Y AVG
+28.85%
FCF Analysis
Free Cash Flow (TTM)
$4.85B
FCF Yield
2.50%
Price/FCF
40.0
Formula: FCF = Operating Cash Flow - Capital Expenditures
Why FCF matters:
- Shows actual cash available (not accounting earnings)
- Funds dividends, buybacks, and debt reduction
- Less susceptible to accounting manipulation than net income
- Key metric for DCF valuation models
Novo Nordisk A/S Free Cash Flow (FCF) Formula & Definition
Free Cash Flow represents the cash a company generates after accounting for capital expenditures. It's the cash available for dividends, buybacks, debt reduction, or reinvestment.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Novo Nordisk A/S Free Cash Flow (FCF) FAQ
- What is the free cash flow (FCF) for Novo Nordisk A/S (NVO)?
- The free cash flow (FCF) for NVO stock is $4.85B.
- What is the TTM average free cash flow (FCF) for Novo Nordisk A/S (NVO)?
- The TTM average free cash flow (FCF) for NVO stock is $7.09B.
- What is the 3Y average free cash flow (FCF) for Novo Nordisk A/S (NVO)?
- The 3Y average free cash flow (FCF) for NVO stock is $8.44B.
- What is the 5Y average free cash flow (FCF) for Novo Nordisk A/S (NVO)?
- The 5Y average free cash flow (FCF) for NVO stock is $7.65B.
- What is the 10Y average free cash flow (FCF) for Novo Nordisk A/S (NVO)?
- The 10Y average free cash flow (FCF) for NVO stock is $6.52B.
- What is the 15Y average free cash flow (FCF) for Novo Nordisk A/S (NVO)?
- The 15Y average free cash flow (FCF) for NVO stock is $4.64B.
- What is the 20Y average free cash flow (FCF) for Novo Nordisk A/S (NVO)?
- The 20Y average free cash flow (FCF) for NVO stock is $3.76B.
Novo Nordisk A/S Free Cash Flow (FCF) History
| DATE | FREE CASH FLOW (FCF) |
|---|---|
| 2025-12-31 | $4.55B |
| 2024-12-31 | $9.64B |
| 2023-12-31 | $10.36B |
| 2022-12-31 | $9.20B |
| 2021-12-31 | $7.28B |
| 2020-12-31 | $4.89B |
| 2019-12-31 | $5.32B |
| 2018-12-31 | $4.95B |
| 2017-12-31 | $5.23B |
| 2016-12-31 | $5.66B |
| 2015-12-31 | $4.64B |
| 2014-12-31 | $4.44B |
| 2013-12-31 | $4.11B |
| 2012-12-31 | $3.28B |
| 2011-12-31 | $3.14B |
| 2010-12-31 | $2.82B |
| 2009-12-31 | $2.36B |
| 2008-12-31 | $2.03B |
| 2007-12-31 | $1.48B |
| 2006-12-31 | $781.35M |
| 2005-12-31 | $762.58M |
| 2004-12-31 | $816.18M |
| 2003-12-31 | $620.01M |
| 2002-12-31 | $149.08M |
| 2001-12-31 | $60.45M |
| 2000-12-31 | $465.59M |
| 1999-12-31 | $273.41M |
| 1998-12-31 | $214.95M |
| 1997-12-31 | $67.82M |
| 1996-12-31 | $-20.31M |
Related Metrics
About Novo Nordisk A/S
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Maziar Mike Doustdar